Drugs / Pembrozilumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05429866 | Sep 2022 → Jun 2024 | breast cancer, colorectal cancer, cutaneous neuroendocrine carcinoma, head and neck cancer +7 | Jules Bordet Institute | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pembrozilumab | “Pembrozilumab” NCT05429866 ↗ |